Rationale: Short-term mechanical circulatory support is increasingly used in the management of cardiogenic shock, but data from controlled studies are sparse. Thus, real-life data on complication rates and predictors of adverse outcome are important. Objective: The objective of this study was to analyse the experience with Impella devices in the management of profound cardiogenic shock. Methods and results: A retrospective study of 109 consecutive patients with severe shock after myocardial infarction, acute heart failure, or cardiac surgery. Possible device-related complications were registered and predictors of death while on Impella support and within 180 days were identified. In 79 patients (72%) cardiogenic shock was caused by myocardial infarction, acute heart failure in 16 (15%) and post-cardiotomy shock in 14 patients (13%). Thirty-five patients (32%) were comatose after cardiac arrest and in seven, the Impella was placed during chest compression. Mean age was 62±12 years, mean arterial pressure was 57±13 mmHg, pH 7.19±0.17 and lactate 7.5±5.7 mmol/l (range 1.8-30.0 mmol/l) at placement. During Impella therapy, 26 patients (28%) died among patients with myocardial infarction or acute heart failure. Of data available prior to placement lactate (hazard ratio 1.14, 95% confidence interval 1.04-1.25, P=0.004) was the only predictor of death on support. During support, five patients (5%) developed leg ischaemia requiring intervention. Bleeding from the Impella insertion site was seen in 14 patients (13%). Conclusion: Impella treatment is feasible in profound cardiogenic shock at an acceptable rate of complications. Despite an aggressive approach to restore cardiac output, mortality was high. Besides the severity of lactic acidosis there were no strong predictors of early death.
Introduction
The outcome of cardiogenic shock remains poor despite aggressive early revascularisation and the increasing use of mechanical circulatory support systems. [1] [2] [3] Data still suggest that mortality often exceeds 50%, making it the leading cause of death following myocardial infarction (MI). 3 Guidelines recommend early revascularisation, vasopressors and inotropes to maintain organ perfusion, and if inadequate, mechanical circulatory support should be considered. 4 Historically, intra-aortic balloon pump (IABP) has been utilised in approximately 50% of cases. However, the IABP-SHOCK II Trial 5 showed no difference in medical therapy and the use of IABP in patients with cardiogenic shock. There has therefore been a decrease in the use of IABP and a simultaneously steep increase in the use of other percutaneous assist devices including extracorporeal membrane oxygenation (ECMO) and the Impella microaxial percutaneous devices. 6 However, the use of mechanical assist devices is based on expert consensus, as comparative studies of the different support systems in a clinical setting are notoriously difficult to perform. 7 Consequently, the available studies with randomised data besides those on IABP are hampered by low power and selection bias. 8, 9 Thus real life data on the use, complication rates and predictors of adverse outcome of patients managed with these systems are clinically important.
The objective of this study was to analyse the experience with the microaxial percutaneous Impella CP, 5.0 and RP devices in the management of profound cardiogenic shock at a tertiary centre with a high volume of primary percutaneous coronary intervention (PCI).
Methods
The study is a single-centre retrospective study including all patients with cardiogenic shock managed with an Impella device between April 2013 and April 2017. The facility is a Danish tertiary centre that provides primary PCI service for approximately 1.2 million inhabitants (approximately 650 primary PCI procedures annually) and performs approximately 1000 cardiac surgical procedures annually.
From electronic patients records and intensive care recordings (PICIS Live Care Solutions) patient demographics and baseline patient characteristics were retrieved, including indications, procedural characteristics, complications of the Impella device, use of vasopressors and inotropes, bleeding complications and the use of mechanical ventilation. Bleeding complications were assessed according to the global use of strategies to open occluded arteries (GUSTO) criteria 10 and acute kidney injury according to the risk, injury, and failure; and loss; and end-stage kidney disease (RIFLE) classification system for acute kidney injury. 11 From echocardiography performed immediately before placement visually estimated left ventricular ejection fraction was recorded. From biochemical analyses peak troponin I and creatine kinase MB, estimated glomerular filtration rate (eGFR) was assessed using the modification of diet in renal disease (MDRD) equation, 12 peak C-reactive protein and peak bilirubin were recorded as well as pH and arterial lactate concentration arterial blood gas taken immediately before placement of the Impella device. For troponin I the highest value reported was 50,000 ng/l and for creatine kinase MB it was 600 µg/l.
A risk class was estimated using the survival after venoarterial extracorporeal membrane oxygenation (VA-ECMO) 12-item (SAVE) score, which has been developed to predict inhospital survival in refractory cardiogenic shock managed with VA-ECMO. 13 Patients were divided into risk classes I to V, in which class I is associated with an estimated 75% hospital survival and class V 18%. 13 The study was approved by the Danish Health and Medicines Authorities (3-3013-1098/1) and Danish Data Protection agency.
The Impella devices (CP, 5.0 and RP) were placed according to expert consensus 14 and recommendations from the manufacturer. The Impella CP, 14 Fr in diameter, was inserted under fluoroscopic guidance in all but one patient, in whom it was placed in the intensive care unit (ICU) with transesophageal echocardiographic guidance. In all cases the Impella CP was placed through the femoral artery using a modified Seldinger technique. The Impella 5.0 is 21 Fr in diameter and was placed by surgical cutdown of the subclavian or femoral artery. An activated clotting time greater than 250 seconds was confirmed at placement and unless there was severe bleeding activated clotting time was kept at 140-180 seconds during support.
Indications for Impella use
The use of the Impella device was left to the discretion of the treating cardiologist/cardiac surgeon. The post-procedure support of the Impella device was managed in an experienced cardiothoracic ICU. Main indications for use of the Impella was MI with cardiogenic shock defined as systolic blood pressure less than 100 mmHg and/or a need for catecholamine therapy and impaired end-organ perfusion with arterial lactate greater than 2.5 mmol/l and left ventricular ejection fraction less than 45%. Primary PCI was performed using standard equipment and techniques as well as dual antiplatelet therapy at the discretion of the treating cardiologist. Whether the Impella device was placed before or after the PCI procedure was recorded.
Patients with acute heart failure (AHF) and cardiogenic shock and patients with post-cardiotomy shock in whom an Impella device was needed for mechanical circulatory support were also recorded. In 25 patients managed with VA-ECMO for post cardiotomy shock, MI, myocarditis or refractory cardiac arrest Impella CP or 5.0 was used as an active vent due to lack of aortic valve opening and left ventricular distension and to expedite weaning from VA-ECMO.
ICU management
The use of cathecolamines (norepinephrine, dopamine and epinephrine) was at the discretion of treating physicians. The first choice vasopressor was norepinephrine. Likewise, the use of inodilators was at the discretion of the treating physician. Generally, milrinone was the preferred drug in the first 24 hours. Thereafter and especially during weaning of the Impella, levosimendan was preferred. In the case of refractory oliguria, hyperkalaemia or uraemia, continuous renal replacement therapy was initiated. During Impella support the target mean arterial pressure (MAP) was generally 65 mmHg and central venous pressure was 10-12 mmHg.
Follow-up
The entire population was assessed for survival up to 180 days through chart review and through the Danish Civil Registration system in which all deaths in Denmark are registered. No patients were lost to follow-up.
Statistics
Continuous Gaussian distributed data are presented as mean ± standard deviation (SD) and categorical data as proportions. Continuous skewed data are presented as median and interquartile range (IQR). Differences in baseline characteristics were compared using the t-test and χ 2 test for continuous and categorical variables, respectively, and Wilcoxon rank-sum test for non-parametric data.
A simple Kaplan-Meier time to event model was used to evaluate survival times for overall survival. Survival curves were compared with the log-rank test. All-cause mortality was assessed using the Cox proportional hazard model to determine predictors of death on Impella support and 180 days overall survival. Due to very different presentations, patients with post-cardiotomy shock were excluded from these analyses. Hazard ratios (HRs) are presented with 95% confidence intervals (CIs). A two-sided P value less than 0.05 was considered statistically significant. Data were analysed using SPSS (IBM Statistics, version 21.0).
Results
At Impella placement MAP was 57±13 mmHg, pH 7.19±0.17 and lactate 7.5±5.7 mmol/l (range 1.8-30.0 mmol/l). The SAVE score was assessable in 93 patients (85%) with a mean score of −9.2±3.6. One patient was in risk class II, six patients were in class III, 49 patients were in class IV and the remaining 37 patients were in risk class V. The indication for Impella support was MI in 79 patients (72%), AHF without MI in 16 (15%) and post-cardiotomy shock in 14 patients (13%), see Table 1 .
MI with cardiogenic shock
The characteristics of 79 patients with MI and shock are presented in Table 1 . Sixty-eight of these patients (86%) had STEMI. In 57 patients (72%) the culprit lesion was in the proximal left anterior descending artery or the left main stem. In seven patients (9%) the device was placed during chest compression. There were three deaths (4%) in the catheterisation laboratory. ICU management of patients is summarised in Table 2 .
In 22 patients (28%) the device was placed before PCI and in this pre-PCI group mortality was lower than in those in whom it was placed after PCI (HR 0.47, 95% CI 0.21-0.98, P=0.04), see Figure 1 . The difference was driven by a lower mortality during support in the patient group in whom the Impella was inserted before the primary PCI (three deaths in 22 patients) compared to 19 deaths in 57 patients in whom the device was inserted after the intervention, P=0.03. Among patients surviving to weaning of the Impella, five of 19 versus 12 of 38 patients died, P=0.68. In the pre-PCI group door to balloon time was significantly longer (median 55 minutes (25th to 75th percentile 33-76 minutes)) than in the post-PCI group (24 minutes (14-33 minutes), P<0.001). Seven patients (32%) in the pre-PCI group had the Impella placed during chest compression. The culprit lesion was left main in nine patients (41%) and proximal left anterior descending artery in 10 (45%) in the pre-PCI group. There were no differences in age (63±9 years vs. 63±12 years, P=0.88), left ventricular ejection fraction (15±9% vs. 17±13%, P=0.49), pH (7.18±0.18 vs. 7.24±0.13, P=0.22), arterial lactate (6.6±3.9 mmol/l vs. 8.0±6.7 mmol/l, P=0.34) or MAP (61±15 mmHg vs. 58±14 mmHg, P=0.35) in patients in whom the Impella was placed before versus after PCI. In patients with pre-PCI the Impella peak creatine kinase MB was lower (median 225 µg/l (87-575)) compared with post-PCI (503 µg/l (135-600), P=0.03. As 60 patients (76%) in the MI group had troponin I exceeding 50,000 ng/l it was not meaningful to compare peak troponin I in patients with pre versus post-PCI placement of the Impella.
AHF with shock
The group of patients with AHF is presented in Table 1 . In four, myocardial biopsy confirmed lymphocytic myocarditis, in three Takotsubo cardiomyopathy was suspected, in four refractory cardiac arrest with normal coronary angiography was seen, and in five patients the cause of heart failure was unknown. All but one patient were successfully weaned from Impella support but subsequently five patients (33%) died during follow-up, see Figure 2 .
Post-cardiotomy shock
In patients with postoperative shock the surgical procedure was an isolated mitral valve procedure in four, in two it was combined aorta valve replacement and coronary artery bypass grafting (CABG) and in the remaining eight patients isolated CABG was performed. Of the isolated CABG procedures five were emergency procedures. In the majority of cases the Impella was placed after VA-ECMO to unload the left ventricle, see Table 2 . The overall mortality among patients supported with the Impella alone was 80% after 180 days and in the combined ECMO Impella group mortality was 67%.
Complications
Complications during ICU stay are summarised in Tables 2  and 3 . Complications that were probably related to Impella treatment included limb ischaemia, which in five patients (5%) was severe and required surgical intervention, and in one of these patients (1%) lower leg amputation was necessary. There were three cases of sudden pump stop requiring placement of a new device in two of the patients. These pump stops were possibly caused by biofilm/thrombus formation. Bleeding from the Impella insertion site requiring treatment was seen in 14 patients (13%), which was managed by reposition of sheath, lowering activated clotting time, removing heparin from purge fluid or manual compression.
Among the 95 patients with cardiogenic shock caused by MI or AHF, there were 26 deaths (28%) while on Impella support, the majority due to multiorgan failure. Patients dying on support had lower pH (7.10±0.21 vs. 7.23±15, P=0.008), higher arterial lactate (10.0±7.5 mmol/l vs. 6.5±5.0 mmol/l, P=0.02), but no difference in age (64±12 years vs. 63±11 years, P=0.71), MAP (55±13 mmHg vs. 58±14 mmHg, P=0.21) or left ventricular ejection fraction (15±13% vs. 18±12%, P=0.46), see Figure 3 . In a Cox multivariable model lactate level prior to Impella insertion was the only independent predictor of death on Impella support, see Table 4 .
Overall, 48 patients died, see Figure 1 . At 6 months, survival in patients supported by an Impella CP was 52%, in patients supported by an Impella 5.0 it was 40% and in patients supported by an Impella RP it was 33%. Six-month mortality in patients in SAVE risk class II or III was 28%, in risk class IV it was 42% and in risk class V it was 65%. In patients with MI or AHF and shock predictors of outcome were age and lactate, see Table 4 .
Discussion
This single-centre study of patients with profound cardiogenic shock treated with mechanical circulatory support using micoaxial pump technology confirms the feasibility of using the Impella device in the acute setting of cardiogenic shock at an acceptable rate of complications. Despite 
Values are number and percentage. *According to GUSTO criteria. MI: myocardial infarction; AHF: acute heart failure. Figure 3 . Death rate while on Impella support in patients with cardiogenic shock caused by myocardial infarction or acute heart failure according to tertiles of age (years), mean arterial pressure (mmHg), lactate (mmol/l) and left ventricular ejection fraction (%) as well as whether patients were comatose after out-of-hospital cardiac arrest or supported by veno-arterial extracorporeal membrane oxygenation.
the aggressive approach to restore cardiac output, mortality was high with one out of four dying from multiorgan failure on support. However, besides the severity of lactic acidosis, there were no strong predictors of early death based on the immediate evaluation of the patient, and even lactate concentrations between groups were highly overlapping with no clear cut off. The Impella device is a miniaturised axial pump that allows for blood to be aspirated from the left ventricle (or inferior vena cava for the RP) and expelled above the aortic valve into the ascending aorta (or pulmonary arteries for the RP), thereby augmenting cardiac output. This unloads the left ventricle during the entire cardiac cycle. 15 Thus wall stress is lowered with improved subendocardial coronary blood flow reducing myocardial oxygen consumption without compromising cardiac output. 16, 17 Thus, from a theoretical standpoint, mechanical support with Impella confers several beneficial effects in the setting of acute left ventricular failure, especially if caused by myocardial ischaemia. 18 Still, cardiogenic shock is an extremely complex condition characterised by an interplay of multiple organ failure, preexisting comorbidity, frailty in which restoration of cardiac output alone may be inadequate to secure survival. We found that 28% of patients died while on support, mainly due to multiorgan failure. This is in agreement with other observational studies suggesting that a substantial number of patients with cardiogenic shock die, despite restoration of cardiac output. 19 Furthermore, the recent IMPRESS trial in which 48 patients with shock on admission were randomly assigned to Impella or IABP failed to demonstrate any survival benefit in the Impella group. 8 Although power was low and the study almost exclusively enrolled comatose out-of-hospital cardiac arrest (OHCA) patients in whom the primary cause of death is anoxic brain injury, the complete lack of benefit is concerning and warrants larger studies in cardiogenic shock excluding comatose OHCA patients. The current data clearly demonstrate the difficulties in selecting patients for mechanical circulatory support. Virtually none of the readily available risk markers when the decision is made to initiate support provided more than weak prognostic information to identify those patients with favourable outcomes or those that died during Impella support. Based on the present data and current literature, patient selection should still be based on individual assessment.
Another issue of great debate is the timing of circulatory support. The present study indicates better survival in patients with placement of the device before revascularisation. This is in agreement with observational data from the USPELLA registry 20 and a single-centre experience from Germany. 21 Furthermore, translational data performed in otherwise healthy mammals with a relatively short duration of coronary occlusion compared to the real life human scenario of ST-segment elevation myocardial infarction (STEMI) does suggest a striking resilience to ischaemic myocardial damage when the left ventricle is unloaded. 16, 17, 22 Restoration of cardiac output as early as possible in a patient in the vicious circle of developing multiorgan failure due to inadequate cardiac output is intuitively beneficial. However, this must be weighed against the deferred opening of the culprit lesion. Even though the Impella in uncomplicated cases can be placed and support initiated in less than 10 minutes, the current data suggest that median door to balloon time was 25-30 minutes longer in the group of patients in whom the Impella was inserted before coronary revascularisation. Irrespective of translational data, this is a concern that should also be addressed in future controlled trials. Complication rates were moderate, but acceptable given the severity of disease in the study population. One of the most concerning complications of Impella support is leg ischaemia, which resulted in below-knee amputation in one case (0.9%). The rate of ischaemia in the present study was lower than what has been reported elsewhere in patients supported with the Impella, 23 and lower than what is seen in patients on peripheral VA-ECMO without support and similar to those with distal protection. 24 Of concern were three episodes of sudden pump stop. Subsequent analysis of Impella console data in two cases revealed an abrupt increase in motor current suggestive of aspiration of thrombus or other material to the device, in which the increase in motor current will cause the device to stop and it will not be possible to restart it. In both cases daily echocardiography had not raised any suspicion of left ventricular thrombus and heparin infusion had not been interrupted. Finally, the data clearly show that with extended support multiple repositions will be required and suction events will occur in many patients. These complication rates illustrate that management and monitoring of such devices requires a level of expertise that can only be obtained in high volume tertiary centres with cardiac and vascular surgery and a 24/7 availability of trained echocardiographers.
Limitations
There are multiple limitations to the data presented. Although representing all patients treated with an Impella during the study period and no patients being lost to followup, the populations are likely to be subject to selection bias. As there was no control group it is unclear whether the device has improved outcomes in this population, and whether similar results could be obtained in less specialised institutions with a lower volume of patients. An alternative strategy to manage patients with refractory cardiogenic shock that is widely used would be to place the patient on VA-ECMO. Using the SAVE risk score we found despite a very high risk class in the present study that mortality in all groups was lower than the SAVE score predicted. 13 However, it is of course purely speculative as to whether the present population would have done differently if managed with VA-ECMO. Furthermore, no definite conclusions can be drawn and data should be considered hypothesis generating. The group with postoperative shock was small and differed in many central aspects from the two other groups, and due to this these patients were excluded from multivariable models but were described to ensure completeness of data. The groups in whom the Impella RP and 5.0 were used were quite small and did not allow separate analysis of these subgroups.
Conclusion
In patients with profound cardiogenic shock mechanical circulatory support with microaxial pump technology is feasible in the acute setting with an acceptable rate of complications. Despite an aggressive approach to restore cardiac output, mortality was high, with 28% of patients dying from multiorgan failure on support. However, besides the initial severity of lactic acidosis, there were no strong predictors of adverse outcomes based on the immediate evaluation of the patient. Future studies should focus on optimal patient selection and timing of placement of these devices.
